Andrew Puca, PhD presents techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs, with a focus on stress-free assessments of glucose measurement and response using continuous glucose monitoring and the banana tolerance test.
The key to fighting type 2 diabetes is to develop and utilize novel agents that control multiple disease aspects, rather than individual diabetes components such as hyperglycemia, hypertension, or dyslipidemia alone. To assess new agents, and facilitate faster progression to the clinic, more clinically relevant preclinical models are needed, that mimic full human disease progression.
Non-human primates (NHP) which spontaneously develop diabetes, show all of the characteristics and comorbidities of human type 2 diabetes at different stages of the progressive disease. They provide the most predictive animal model system for preclinical diabetes research, and are combined with novel techniques to reduce invasiveness and stress, leading to improved clinical outcomes and study data.
In this webinar hosted by CrownBio, Dr. Andrew Puca explores unique techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs. He focuses on stress free assessments of glucose measurement and response in NHPs using continuous glucose monitoring and the banana tolerance test.
What You Will Learn:
- New solutions to common challenges in preclinical diabetes research
- How to utilize spontaneously diabetic NHPs to generate the most clinically relevant and robust preclinical data
- How to implement continuous glucose monitoring (CGM) and banana tolerance tests (BTT)
- That CGM and BTT provide less stressful and minimally invasive techniques, providing optimized glucose measurement and response data
- How reducing stress in NHPs leads to improved datasets
Who Should Watch:
- Preclinical scientists who use NHP models for diabetes and metabolic disease drug discovery
- Diabetes and metabolic disease researchers working with animal models
- Drug discovery scientists evaluating new models and techniques for diabetes related research
Andrew Puca, PhD
Senior Business Development Director
Dr. Andrew Puca has extensive experience in preclinical drug development, partnering with clients to optimize the translatability of their metabolic disease programs. Since joining CrownBio in 2016, Andrew’s scientific focus has been on translational animal models of cardiovascular and metabolic disease including obesity, type 2 diabetes, NAFLD/NASH, dysmetabolism, and diabetic nephropathy.
Andrew received his Ph.D. in Cellular and Molecular Biology from Università degli Studi di Siena and completed his postdoctoral research at Temple University, specializing in stem cell biology and regenerative medicine. He has over 10 years of translational research experience and has authored 15 publications.